Insider Trading Alert - BRCD, OPK And PACW Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 11, 2014, 134 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $363.00 to $110,557,762.60.

Highlighted Stocks Traded by Insiders:

Brocade Communications Systems (BRCD) - FREE Research Report

Cheng Ken who is CTO & VP Corporate Development at Brocade Communications Systems sold 15,000 shares at $10.13 on March 11, 2014. Following this transaction, the CTO & VP Corporate Development owned 325,727 shares meaning that the stake was reduced by 4.4% with the 15,000-share transaction.

The shares most recently traded at $10.14, up $0.01, or 0.14% since the insider transaction. Historical insider transactions for Brocade Communications Systems go as follows:

  • 12-Week # shares sold: 7,175
  • 24-Week # shares sold: 7,175

The average volume for Brocade Communications Systems has been 5.3 million shares per day over the past 30 days. Brocade Communications Systems has a market cap of $4.4 billion and is part of the technology sector and computer hardware industry. Shares are up 15.06% year-to-date as of the close of trading on Friday.

Brocade Communications Systems, Inc. provides Internet protocol based networking solutions and storage area networking (SAN) solutions to businesses and organizations worldwide. The company has a P/E ratio of 15.0. Currently there are 4 analysts that rate Brocade Communications Systems a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BRCD - FREE

TheStreet Quant Ratings rates Brocade Communications Systems as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Brocade Communications Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 9,600 shares at $9.21 on March 11, 2014. Following this transaction, the CEO & Chairman owned 139.5 million shares meaning that the stake was reduced by 0.01% with the 9,600-share transaction.

The shares most recently traded at $9.24, up $0.03, or 0.31% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.1 million shares per day over the past 30 days. Opko Health has a market cap of $3.7 billion and is part of the health care sector and health services industry. Shares are up 6.52% year-to-date as of the close of trading on Friday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PacWest Bancorp (PACW) - FREE Research Report

Eggemeyer John M Iii who is Director at PacWest Bancorp sold 30,000 shares at $44.48 on March 11, 2014. Following this transaction, the Director owned 250,517 shares meaning that the stake was reduced by 10.69% with the 30,000-share transaction.

Wolff Jared M who is EVP, GC & Reg. Pres. at PacWest Bancorp sold 55,000 shares at $44.62 on March 11, 2014. Following this transaction, the EVP, GC & Reg. Pres. owned 29,930 shares meaning that the stake was reduced by 64.76% with the 55,000-share transaction.

Santoro Victor R who is Exec Vice President and CFO at PacWest Bancorp sold 5,000 shares at $44.33 on March 11, 2014. Following this transaction, the Exec Vice President and CFO owned 146,222 shares meaning that the stake was reduced by 3.31% with the 5,000-share transaction.

The shares most recently traded at $44.77, up $0.44, or 0.98% since the insider transaction. Historical insider transactions for PacWest Bancorp go as follows:

  • 4-Week # shares bought: 8,000
  • 4-Week # shares sold: 13,433
  • 12-Week # shares bought: 8,000
  • 12-Week # shares sold: 13,433
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 53,059

The average volume for PacWest Bancorp has been 589,200 shares per day over the past 30 days. PacWest Bancorp has a market cap of $2.0 billion and is part of the financial sector and banking industry. Shares are up 6.82% year-to-date as of the close of trading on Friday.

PacWest Bancorp operates as the bank holding company for Pacific Western Bank that provides commercial banking products and services to small to medium sized businesses, and the owners and employees of those businesses primarily in Southern California. The stock currently has a dividend yield of 2.22%. The company has a P/E ratio of 41.4. Currently there are 6 analysts that rate PacWest Bancorp a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PACW - FREE

TheStreet Quant Ratings rates PacWest Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full PacWest Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%